ライフサイエンスコーパス: wheeze

1 eeze, early transient wheeze, and persistent wheeze).

2 oup had higher rates of early and persistent wheeze.

3 ptibility to early infections and persistent wheeze.

4 as also examined if accompanied by recurrent wheeze.

5 ons during infancy and subsequent persistent wheeze.

6 qually associated across LCADs that included wheeze.

7 ment of allergic sensitization and recurrent wheeze.

8 mples of children who went on to have atopic wheeze.

9 ma, and in preschool children with recurrent wheeze.

10 RSV-induced illness and subsequent recurrent wheeze.

11 to time to the onset of asthma or recurrent wheeze.

12 28]), and we associated them with asthma and wheeze.

13 nses at birth were associated with recurrent wheeze.

14 associated with later development of atopic wheeze.

15 t associations for allergic and non-allergic wheeze.

16 of asthma if started in the young child with wheeze.

17 sitization, and only five reported on asthma/wheeze.

18 on) and direct effects of sRAGE on recurrent wheeze.

19 determine the course of asthma and recurrent wheeze.

20 itis who are at risk of developing recurrent wheezing.

21 cell debris, and increased risk of recurrent wheezing.

22 to identify (latent) phenotypes of childhood wheezing.

23 fined as >=3 episodes of physician-diagnosed wheezing.

24 en at increased risk of developing recurrent wheezing.

25 follow-up at 3 years, and 31% had recurrent wheezing.

26 cts the airways and presents as coughing and wheezing.

27 abolite of di-isodecyl phthalate (DIDP), and wheezing.

28 to promote airway obstruction and recurrent wheezing.

29 d with a higher risk for allergy, asthma and wheezing.

30 crobiota abundances to the risk of recurrent wheezing.

31 due to concerns over its potential to induce wheezing.

32 ficantly associated (p < 0.05) with allergic wheeze (18 positive, 1 negative) and 21 pesticides with

33 egative) and 21 pesticides with non-allergic wheeze (19 positive, 2 negative); 11 pesticides were ass

34 cara spp. seropositivity was associated with wheeze (2.97[1.45- 7.76]), hayfever (4.03[1.63-9.95]), e

35 r fever (20% vs 16%) and less likely to have wheeze (30% vs 38%; all P < .05).

36 had a significantly higher rate of recurrent wheeze (33% vs 64%; hazard ratio, 2.23; 95% CI, 1.00-4.9

37 , P = 0.033) and more likely to present with wheeze (35% versus 25%, P = 0.031) than those with HRV-A

38 food allergy (4[3%] of 124 vs 2[1%] of 154), wheeze (39[31%] of 127 vs 45[29%] of 154), and atopic se

39 ness of breath (1.86, 0.97-3.57; p<0.1), and wheeze (4.00, 1.52-10.50; p<0.05) after walking down Oxf

40 rs; 77% phlegm; 70% shortness of breath; 47% wheezing; 46% chest pain; 42% abnormal peak flow), 334 (

41 n with asthma and 54 preschool children with wheezing [68.2% of whom were atopic]) were included in t

42 Asthma/wheezing accounted for 10%-18% of total 5-year physician

43 = .025; 0.80 [0.74,0.86], P < .001; current wheeze, AD and rhinitis).

44 1,356) was associated with elevated risk of wheeze, adjusting for pregnancy complications, maternal

45 rt through age 7 years, reflecting symptoms (wheezing), aeroallergen sensitization, pulmonary functio

46 tors which formed the basis of the MAAS APT: wheeze after exercise; wheeze causing breathlessness; co

47 Patterns of wheezing, allergic sensitization, and lung function iden

48 lass mixed models identified trajectories of wheezing, allergic sensitization, and pulmonary function

49 the 6-year incidence of asthma and recurrent wheeze among children who were at risk for asthma.

50 ed pesticides with allergic and non-allergic wheeze among male farmers.

51 elial cells from 63 children with or without wheeze and accompanying atopy, using differential gene e

52 saturated fatty acid (PUFA) intake and child wheeze and asthma have been inconsistent.

53 Recurrent wheeze and asthma in childhood are commons causes of chr

54 ver, studies investigating associations with wheeze and asthma in later childhood are scarce and did

55 nse, at higher risk for developing recurrent wheeze and asthma.

56 ever, as it was not strongly associated with wheeze and atopy, and airway obstruction was less revers

57 We defined allergic wheeze as reporting both wheeze and doctor-diagnosed hay fever (n = 1,310, 6%) an

58 nsive care use) and chronic (e.g., recurrent wheeze and infections) morbidities in young children, th

59 ren at risk of persistent asthma (defined as wheeze and presence of airflow limitation or airway hype

60 00 days of life on the development of atopic wheeze and provide additional support for considering mo

61 piratory allergic disease symptoms including wheeze and rhinitis at 7 y CA were the main outcomes.

62 Allergic diseases (eczema, wheeze and rhinitis) in children often present as hetero

63 tronger associations for LCADs with comorbid wheeze and rhinitis.

64 ciations between prevalence of self-reported wheeze and shortness of breath and annual mean particula

65 lution was associated with the prevalence of wheeze and shortness of breath in this large study, with

66 o NO2 also showed positive associations with wheeze and shortness of breath.

67 Monophonic wheezes and stridor were heard over the anterior neck, w

68 and early life are associated with recurrent wheezing and aeroallergen sensitivity and altered cytoki

69 ied and mainly differentiated by patterns of wheezing and allergic sensitization (low wheeze/low atop

70 t of physician-diagnosed asthma or recurrent wheezing and allergic sensitization to food or environme

71 atory morbidity among children with frequent wheezing and allergic sensitization.

72 asurements, and assessed physician-diagnosed wheezing and asthma by questionnaires.

73 n 3 expression and correlated inversely with wheezing and asthma in nonatopic subjects.

74 y microbiome in the development of recurrent wheezing and asthma remains uncertain, particularly in t

75 thma risk factors and the natural history of wheezing and asthma through childhood and beyond.

76 lationship with the development of recurrent wheezing and asthma.

77 erventions that could decrease virus-induced wheezing and asthma.

78 blings, reported childcare attendance, early wheezing and eczema in the first 3 years of life.

79 n of maternal stress/depression to recurrent wheezing and peripheral blood mononuclear cell cytokine

80 similarity irrespective of airway symptoms (wheeze) and allergy.

81 lergic sensitization, lung function, current wheeze, and asthma (n = 1405) were investigated using re

82 Eczema, wheeze, and immune function outcomes were assessed at 6

83 mid-childhood onset wheeze, early transient wheeze, and persistent wheeze).

84 n palpation of the anterior neck, expiratory wheezes, and crackles heard at auscultation of bases of

85 were more likely to have chest retractions, wheezing, and a history of underlying asthma/reactive ai

86 also observed between 2,5-dichlorophenol and wheezing, and between monocarboxynonyl phthalate, a meta

87 ronic respiratory conditions such as asthma, wheezing, and bronchitis.

88 ma including maternal atopy, early childhood wheezing, and bronchodilator response.

89 rhea, restlessness/sleep disturbances, minor wheezing, and cold extremities).

90 yfish product (100g), he experienced nausea, wheezing, and erythema and had visited our hospital.

91 Five-year cumulative all-cause, asthma/wheezing, and respiratory event-related hospitalization

92 range increase in NO2 [2.2 ppb]) and current wheeze (aOR, 1.14; 1.02-1.28).

93 In addition to parental asthma, eczema, and wheezing apart from colds, variables that predicted asth

94 Although respiratory symptoms, including wheezing, are common in preterm-born subjects, the natur

95 pattern with higher hazard ratios for asthma/wheeze around ages 5 and 18 months.

96 We defined allergic wheeze as reporting both wheeze and doctor-diagnosed hay

97 d hay fever (n = 1,310, 6%) and non-allergic wheeze as reporting wheeze but not hay fever (n = 3,939,

98 ment of allergic sensitization and recurrent wheeze assessed at age 3 years.

99 ntibody is available; (b) rhinovirus-induced wheezing, associated with atopic predisposition of the p

100 Early-life wheezing-associated respiratory infection with human rhi

101 Early-life wheezing-associated respiratory tract infection by rhino

102 ic disease outcomes including sensitization, wheeze, asthma, and eczema were collected at multiple fo

103 -term lung health, with potential effects on wheezing, asthma, and chronic lung disease.

104 tions between prenatal PUFA status and child wheeze/asthma and modifying effects of maternal asthma/a

105 d a higher ratio had the highest risk across wheeze/asthma outcomes (P(interaction) < .05).

106 Child wheeze/asthma outcomes ascertained at age 4 to 6 years i

107 s between prenatal PUFA status and childhood wheeze/asthma were modified by maternal history of asthm

108 of eczema; 14, allergic sensitization; nine, wheezing/asthma; six, food allergy; three, allergic rhin

109 onary function and decrease the incidence of wheeze at 1 year of age.

110 Overall, 166 (36%) children had recurrent wheeze at age 3 years.

111 ve a lower incidence of asthma and recurrent wheeze at the age of 6 years than would those born to mo

112 oking, higher maternal education levels, and wheezing at age 36-72 months.

113 ness at baseline and the onset of asthma and wheezing at the age of 7.

114 isease (eczema, atopic eczema, food allergy, wheeze, atopic sensitization) was assessed in a subgroup

115 wheeze in the previous 12 months or (b) >=3 wheeze attacks in the previous 12 months.

116 atopy (OR = 0.35, 95% CI = 0.13-0.90), fewer wheezing attacks (OR = 0.40, 95% CI = 0.17-0.97; >3 vs <

117 the underlying pathophysiology of asthma and wheeze between preschool and school-aged children.

118 ing mediated the association between MOD and wheeze but not food allergy.

119 10, 6%) and non-allergic wheeze as reporting wheeze but not hay fever (n = 3,939, 18%); men without w

120 who have never wheezed (NW, n = 389) or have wheezed but had no severe exacerbations (WNE, n = 338).

121 gitudinal prevalence of fever, coughing, and wheezing but increased incidence and longitudinal preval

122 were significantly associated with recurrent wheezing but not increased atopy or reduced antiviral re

123 with a greater risk of developing recurrent wheezing, but with currently available tools, it is impo

124 r risk of offspring with asthma or recurrent wheeze by age 3 years (P(for trend) = .008).

125 sociation with risks of developing recurrent wheeze by age 3 years and asthma by age 5 years.

126 Of 336 children with physician-confirmed wheeze by age 3 years, 117(35%) had school-age asthma.

127 tcome was offspring with asthma or recurrent wheeze by age 3 years.

128 t intensive care and 32% developed recurrent wheeze by age 3 years.

129 sive care unit) and development of recurrent wheeze by age 3 years.

130 8/887 children (56%) had physician-confirmed wheeze by age 8 years, of whom 160 had at least one seve

131 associated with increased risk of recurrent wheezing by age 3 years and asthma that persisted throug

132 Recurrent wheezing by age 3 years was defined based on parental re

133 ospitalization was associated with recurrent wheezing by age 3 years, possibly providing new avenues

134 eal microbiota, and development of recurrent wheezing by age 3 years.

135 and 3 later points to the risk of recurrent wheezing by age 3 years.

136 asis of the MAAS APT: wheeze after exercise; wheeze causing breathlessness; cough on exertion; curren

137 ory symptoms [apnea, stridor, nasal flaring, wheezing, chest indrawing, and/or central cyanosis]) wer

138 no fevers, chills, night sweats, hemoptysis, wheezing, chest pain, palpitations, orthopnea, paroxysma

139 rhinovirus (RV) is most commonly detected in wheezing children thereafter.

140 se bronchodilators to manage childhood acute wheezing conditions in the emergency department (ED), an

141 ariable airflow obstruction and intermittent wheezing, cough, and dyspnea.

142 7/17,063 (72%) term-born children had recent wheeze data for 3 or 4 time points.

143 nd those without postbronchiolitis recurrent wheeze, defined as >=3 episodes of physician-diagnosed w

144 rnal asthma on childhood asthma or recurrent wheeze development.

145 en identified as risk factors for persistent wheeze development.

146 hout asthma on childhood asthma or recurrent wheeze development.

147 case status, especially among children with wheezing disease.

148 contribute to the development of early life wheezing disorders and asthma, and discuss the external

149 risk of hospitalization for asthma and other wheezing disorders, compared to both parents being Hong

150 its use in children with asthma or recurrent wheeze due to concerns over its potential to induce whee

151 eroids in those with severe illness; and (c) wheeze due to other viruses, characteristically likely t

152 risk alleles at the 17q21 genetic locus who wheeze during rhinovirus illnesses have a greatly increa

153 eterogeneous disease, often manifesting with wheeze, dyspnea, chest tightness, and cough as prominent

154 erized by episodic or persistent symptoms of wheezing, dyspnea, and cough.

155 never/infrequent wheeze, mid-childhood onset wheeze, early transient wheeze, and persistent wheeze).

156 s positively associated with risk for asthma/wheeze, eczema, and sensitization at 10 years; adjustmen

157 heeze with later-onset rhinitis," "Transient wheeze," "Eczema only" and "Rhinitis only" were used as

158 steroid-naive children with the first severe wheezing episode (90% hospitalized/10% emergency departm

159 piratory syncytial virus/rhinovirus-negative wheezing episode (adjusted OR, 8.0; P = .001), first whe

160 istics during the first severe virus-induced wheezing episode are associated with pulmonary function

161 episode (adjusted OR, 8.0; P = .001), first wheezing episode at age less than 12 months (adjusted OR

162 d of 76 children presenting with their first wheezing episode at the ages of 3 to 23 months.

163 ensitization at the time of the first severe wheezing episode is an important early risk factor for i

164 topic sensitization at the time of the first wheezing episode were more often likely to develop bronc

165 uffering from severe bronchiolitis (or first wheezing episode): (a) respiratory syncytial virus (RSV)

166 c subjects are uniquely susceptible to acute wheezing episodes provoked by rhinovirus.

167 Maternal stress, depression, and childhood wheezing episodes were assessed by quarterly questionnai

168 a population-based birth cohort with severe wheeze exacerbations confirmed in healthcare records.

169 t-acting bronchodilators to treat asthma and wheeze exacerbations in children 0-18 years presenting t

170 rapeutic options to decrease the severity of wheezing exacerbations caused by respiratory viral infec

171 ue of the use of oral corticosteroids during wheezing exacerbations in preschool-aged children by dem

172 ontribute to the association between MOD and wheeze/food allergy.

173 l-age and 131 preschool children with asthma/wheeze from the Unbiased BIOmarkers for the PREDiction o

174 Participants with asthma and/or wheezing from 4 independent cohorts were included; Breat

175 al responses, preschool children with severe wheeze had impaired airway epithelial proliferative resp

176 Early life aeroallergen sensitization and RV wheezing had additive effects on asthma risk at adolesce

177 sociated with an increased risk of recurrent wheezing (hazard ratio [HR] of 1.38 and 95% high-density

178 ime points for data collection to understand wheeze heterogeneity, and ascertain the association of c

179 heeze/low atopy; high wheeze/low atopy; high wheeze/high atopy).

180 gic sensitization (low wheeze/low atopy; low wheeze/high atopy; transient wheeze/low atopy; high whee

181 The high-wheeze/high-atopy phenotype was associated with low hous

182 tory tract infection history during infancy, wheezing history to 5 age years, and ensuing maturation

183 3) and significantly lower rate of recurrent wheeze (HR 0.58; 95%CI 0.36-0.94; P=0.03).

184 associated with a greater risk of recurrent wheezing (HR, 1.76; 95% HDI, 1.15-3.27).

185 Wheezing illnesses among young children are common and a

186 Early life rhinovirus (RV) wheezing illnesses and aeroallergen sensitization increa

187 o new strategies for the prevention of viral wheezing illnesses and perhaps reduce the subsequent ris

188 (eg, airway microbiome) promote more severe wheezing illnesses and the risk for progression to asthm

189 ds and the predominant microbes during acute wheezing illnesses are both associated with the subseque

190 RSV-induced wheezing illnesses during infancy influence respiratory

191 The etiology and timing of viral wheezing illnesses during the first 3 years of life were

192 isease in childhood and is often preceded by wheezing illnesses during the preschool years.

193 Viral infections are closely linked to wheezing illnesses in children of all ages.

194 was most strongly associated with outpatient wheezing illnesses with RV and aeroallergen sensitizatio

195 During wheezing illnesses, detection of rhinoviruses and predom

196 nd early life stress may influence childhood wheezing illnesses, potentially through effects on immun

197 The associations between viral wheezing illnesses, presence and pattern of aeroallergen

198 re associated with the development of atopic wheeze in a nonindustrialized setting.

199 effects of gut microbial dysbiosis on atopic wheeze in a population living in a distinct developing w

200 tion-wide registers, both as incident asthma/wheeze in age 0-8 years and current asthma at ages 2, 3,

201 in D supplementation on asthma and recurrent wheeze in either an intention-to-treat analysis or an an

202 tamin D supplementation and asthma/recurrent wheeze in offspring at 3 years.

203 n pregnancy and the risk of asthma/recurrent wheeze in offspring.

204 of coexpressed genes associated with atopic wheeze in the lower airway, which could equally distingu

205 ater than 30 ng/mL, reduced asthma/recurrent wheeze in the offspring through age 3 years, suggesting

206 g was protective in both groups, except late wheeze in the preterm group.

207 reported (a) physician-diagnosed asthma and wheeze in the previous 12 months or (b) >=3 wheeze attac

208 was defined as a physician's diagnosis plus wheeze in the previous year.

209 plementation to prevent asthma and recurrent wheeze in young children, which suggested that supplemen

210 d-dose prenatal vitamin D supplementation on wheezing in children at the age of 3 years extends the f

211 ed significantly increased risk of recurrent wheezing in children with profile A (hazard ratio, 2.64;

212 detect atopy in individuals with asthma and wheezing in cohorts with different age groups and could

213 linked to the pathogenesis of viral-induced wheezing in early life.

214 tions and has been associated with decreased wheezing in the first years of life.

215 ple per household, US region, and history of wheezing in the past year), household endotoxin level wa

216 infection and subsequent childhood recurrent wheeze, in comparison to those who were healthy or those

217 ajority of children with asthma or recurrent wheeze, including those whose asthma is categorized as s

218 risk factors facilitating severe asthma and wheezing, including airborne viruses, smoke, indoor damp

219 s predicting the development of asthma among wheezing infants.

220 Although early childhood wheeze is common, persistent asthma is less common.

221 t of serum sRAGE on development of recurrent wheeze is mediated through acute severity.

222 Effect of sRAGE on development of recurrent wheeze is potentially driven through pathways other than

223 Wheezing is common in childhood.

224 high atopy; transient wheeze/low atopy; high wheeze/low atopy; high wheeze/high atopy).

225 /low atopy; low wheeze/high atopy; transient wheeze/low atopy; high wheeze/low atopy; high wheeze/hig

226 of wheezing and allergic sensitization (low wheeze/low atopy; low wheeze/high atopy; transient wheez

227 ess, and depression were highest in the high-wheeze/low-atopy phenotype.

228 udinal wheeze trajectories (never/infrequent wheeze, mid-childhood onset wheeze, early transient whee

229 tion (particularly by 2 years) in the asthma/wheeze models reduced 25(OH)D associations with these la

230 f boiled jellyfish, he experienced erythema, wheezing, nausea, and abdominal pain.

231 ation trajectories with those who have never wheezed (NW, n = 389) or have wheezed but had no severe

232 ific IgE levels and strongly associated with wheeze (odds ratio [OR], 5.64 [95% CI, 3.07-10.52] and 4

233 95% CI, 1.14-6.06; P = .024) and persistent wheeze (odds ratio, 4.24; 95% CI, 1.60-11.24; P = .004)

234 predicted asthma in the PARS included early wheezing (odds ratio [OR], 2.88; 95% CI, 1.52-5.37), sen

235 Acute attacks of wheeze or asthma are among the most common reasons for p

236 cesarean delivery (CD) increased the risk of wheeze or food allergy in early childhood compared with

237 aben concentrations with asthma or recurrent wheeze or food or environmental sensitization at age 3 y

238 o below the lower limit of normal, asthma as wheeze or medication use in 12 months or self-reported p

239 Symptoms of wheeze or rhinitis at 7 y CA did not differ between high

240 demonstrable change in self-reported current wheezing or asthma (adjusted odds ratio 0.81, 95% CI 0.6

241 of the prevalence and severity of recurrent wheezing or asthma in children aged up to 6 years.

242 utcome of interest was self-reported current wheezing or asthma, defined as having medicines prescrib

243 associated with offspring hayfever, eczema, wheezing or asthma.

244 After confirming that there was no wheezing or respiratory symptoms, the lung sound spectru

245 etween-group differences in the incidence of wheezing or shortness of breath.

246 pite this, they had similar rates of current wheezing (OR = 0.93, 95% CI = 0.65-1.32) and were less l

247 osed patients, aged 18-80 years, with cough, wheeze, or dyspnoea and less than 20% bronchodilator rev

248 with asthma symptoms; and days of coughing, wheezing, or chest tightness) across 6, 9, and 12 months

249 was significantly associated with recurrent wheezing (P </= 0.01).

250 aire symptom scores (p=0.037), and increased wheezing (p=0.018), but no evidence of an association wi

251 ase," "Atopic march," "Persistent eczema and wheeze," "Persistent eczema with later-onset rhinitis,"

252 to adolescence, our analysis of longitudinal wheeze phenotypes allowed us to visualize four longitudi

253 We used LCA to derive wheeze phenotypes among 3167 participants in the ALSPAC

254 a major influence on the number and type of wheeze phenotypes identified by using LCA in longitudina

255 eastmilk fatty acid composition and specific wheeze phenotypes or doctor-diagnosed asthma.

256 , and ascertain the association of childhood wheeze phenotypes with asthma and lung function in adult

257 Asthma was most often present in the high-wheeze phenotypes, with greatest respiratory morbidity a

258 y-life aeroallergen exposure was low in high-wheeze phenotypes.

259 l milk fatty acid composition with childhood wheezing phenotypes and asthma up to age 13 years using

260 Adjusted risk ratios with parent-reported wheezing phenotypes and doctor-diagnosed asthma were com

261 rm-born subjects, the natural history of the wheezing phenotypes and the influence of early-life fact

262 teristics were similarly associated with the wheezing phenotypes in both groups, the preterm-born gro

263 We used data-driven methods to define wheezing phenotypes in preterm-born children and investi

264 early-life factors and characteristics with wheezing phenotypes was similar between preterm- and ter

265 Four wheezing phenotypes were defined for both groups: no/inf

266 The presence of fever and wheeze predicted treatment failure.

267 pregnancy is necessary for asthma/recurrent wheeze prevention in early life.

268 l VD level on early life asthma or recurrent wheeze progression to active asthma at age 6 years.

269 trend was reiterated in asthma or recurrent wheeze progression to active asthma from age 3 to 6 year

270 The trend in asthma and recurrent wheeze proportions across the maternal groups' children

271 causes exacerbations of asthma and preschool wheeze (PSW).

272 hort who had complete information on current wheeze recorded at 14 time points from birth to age 161/

273 All-cause, respiratory-related, and asthma/wheezing-related 5-year average cumulative costs were me

274 t setting and respiratory-related and asthma/wheezing-related costs.

275 verity of any symptoms; and the incidence of wheeze, rhinitis, rhinoconjunctivitis, and eczema from b

276 Parent-reported symptoms of wheeze, rhinitis, rhinoconjunctivitis, or eczema from bi

277 Intensive MDA had no effect on wheezing (risk ratio [RR] 1.11, 95% confidence interval

278 iffer between high- and standard-DHA groups [wheeze: RR: 1.10; 95% CI: 0.73, 1.65; P = 0.66; rhinitis

279 Recurrent wheeze (RW) is frequent in childhood.

280 flow obstruction characterised clinically by wheezing, shortness of breath, and coughing.

281 Primary outcomes were recent wheezing, skin prick test positivity (SPT), and allergen

282 ed history of diagnosis by a physician or by wheezing symptoms in the preceding 12 months.

283 ded ever physician-diagnosed asthma, current wheeze (symptoms past 12 months), current asthma (diagno

284 roportion of preterm-born children had early wheeze that resolved with time.

285 es allowed us to visualize four longitudinal wheeze trajectories (never/infrequent wheeze, mid-childh

286 Asthma and recurrent wheezing until age 3 years were recorded.

287 tion) and clinical allergy-related outcomes (wheeze, urticaria, rhinitis and visible flexural dermati

288 ), whereas the association between PM2.5 and wheeze was limited to lower-income participants [OR=1.30

289 Recent wheeze was more common at all time points in the preterm

290 Infant's wheeze was reported by questionnaire every 4-6 months un

291 iratory tract infections or "transient early wheeze" was unaffected.

292 Data on preschool wheeze were extracted from primary-care records.

293 with physician-diagnosed asthma or recurrent wheeze were recruited, including 208 (44%) prescribed hi

294 not hay fever (n = 3,939, 18%); men without wheeze were the referent.

295 it inflammation have efficacy for RV-induced wheezing, whereas the anti-RSV mAb palivizumab decreases

296 zema with later-onset rhinitis," "Persistent wheeze with later-onset rhinitis," "Transient wheeze," "

297 One vaccinee had grade 2 wheezing with rhinovirus but without concurrent LID/Delt

298 When adjusted for all viral etiologies, wheezing with RV (odds ratio = 3.3; 95% CI, 1.5-7.1), bu

299 hing was reported nearly 46% more often than wheezing, with 42.5% (17/40) coughing until the point of

300 on (defined as COPD exacerbation, tachypnea, wheezing, worsening bronchitis, worsening dyspnea, influ